Haymarket MediaLow-Dose Erlotinib an Option for Frail or Elderly Patients w. NSCLC?
According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.